Lenvima, containing the active ingredient Lenvatinib, is a potent oral tyrosine kinase inhibitor (TKI) used primarily for the treatment of various cancers. It works by blocking specific proteins involved in tumor growth and angiogenesis.

Uses

• Thyroid Cancer: Treatment of radioactive iodine-refractory differentiated thyroid cancer (DTC).

• Renal Cell Carcinoma (RCC): Used in combination with everolimus for advanced RCC after one prior anti-angiogenic therapy.

• Hepatocellular Carcinoma (HCC): First-line treatment for patients with unresectable HCC.

• Endometrial Carcinoma: Used in combination with pembrolizumab for advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).

Mechanism of Action

Lenvatinib inhibits multiple receptor tyrosine kinases (RTKs), including vascular endothelial growth factor receptors (VEGFR1, VEGFR2, VEGFR3), fibroblast growth factor receptors (FGFR1-4), and other pathways that promote cancer cell proliferation and angiogenesis.

Onset and Duration of Action

• Onset: Effects on tumor growth can vary depending on the cancer type and patient response.

• Duration: Typically requires continuous treatment as prescribed.

Dosage and Administration

• Thyroid Cancer: 24 mg once daily until disease progression or unacceptable toxicity.

• Renal Cell Carcinoma: 18 mg in combination with 5 mg everolimus once daily.

• Hepatocellular Carcinoma: 8 mg for patients <60 kg, 12 mg for patients ≥60 kg, once daily.

• Endometrial Carcinoma: 20 mg once daily in combination with pembrolizumab.

Side Effects

Common side effects:

• Hypertension

• Fatigue

• Diarrhea

• Nausea

• Weight loss

• Decreased appetite

Serious adverse reactions:

• Cardiac failure

• Liver dysfunction

• Renal impairment

Precautions

• Monitor blood pressure regularly.

• Use caution in patients with hepatic or renal impairment.

• Avoid in pregnancy due to potential harm to the fetus.

Storage

Store at room temperature, away from moisture and heat.